[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 20px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 10px 0px 0px;”][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/06/vbrown1.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_image type=”none” src=”http://beatcc2018.wpengine.com/wp-content/uploads/2017/04/penn-state-hershey.png” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][x_line style=”border-top-width: 1px;”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”2/3″ style=”padding: 0px;”][cs_text class=”cs-ta-left”]

Valerie I. Brown, MD, PhD

Penn State Children’s Hospital

[/cs_text][cs_text]Dr. Brown is the Director of Experimental Therapeutics, Leader of the Experimental Therapeutics Research and Clinical Team (ExTRaCT), and Director of the Fellowship Program of the Division of Pediatric Hematology/Oncology, Department of Pediatrics at Penn State Children’s Hospital.

Appointments: (717) 531-3097 to schedule (Suzanne Treadway, research nurse coordinator).

Division of Pediatric Hematology/Oncology
500 University Drive
P.O. Box 850
Hershey, PA 17033-0850

Phone: (717) 531-3097 (research nurse coordinator)

E-mail: streadway@pennstatehealth.psu.edu (research nurse coordinator)
[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][x_tab_nav type=”three-up” float=”top”][x_tab_nav_item title=”Background” active=”true”][x_tab_nav_item title=”Education” active=”true”][x_tab_nav_item title=”Selected Publications” active=”false”][/x_tab_nav][x_tabs][x_tab active=”true”]Dr. Brown is a Pediatric Oncologist and Hematopoietic Stem Cell Transplantation (HSCT) Specialist at Penn State Health Children’s Hospital located in Hershey, PA. Currently, she is the Director of Experimental Therapeutics and Leader of the Experimental Therapeutics Research and Clinical Team (ExTRaCT) in the division of Pediatric Hematology/Oncology. The Experimental Therapeutics Program and ExTRaCT are supported by Four Diamonds, THON and Mini-THON. She is Associate Professor of Pediatrics at Penn State College of Medicine. She is also the Director of the Pediatric Hematology/Oncology Fellowship Program. The infrastructure within the Division of Pediatric Hematology/Oncology at Penn State Children’s Hospital provides comprehensive care to infants, children, adolescents and young adults using a multidisciplinary team approach with patients and their families being at the center of the healthcare team. This team extends beyond Pediatric Hematology/Oncology including the expertise of many other pediatric specialists at Penn State Children’s Hospital and at Penn State Cancer Institute, resulting in a cohesive network to meet the needs of all of our patients and their families. In addition to the outstanding clinical care enterprise, our basic science and translational laboratory research endeavors are thriving within our division as well as on the Penn State Health Medical Center campus at large. All of these resources and efforts together create an outstanding environment in which innovative therapies can be translated directly to the patient’s bedside.

Dr. Brown has had a long-standing professional interest in discovering new strategies to treat childhood cancer that include biologically-relevant approaches with the goal of maximizing cure rates while minimizing short- and long-term toxicities. Early on, she developed an expertise in understanding the “deranged network wiring” within a leukemia cell sustained its growth and survival and then how best to “short circuit” the leukemia cell such that it is no longer viable or, at least, more vulnerable to conventional chemotherapy. This early work contributed to the development of novel, biologically- targeted treatment strategies for acute lymphoblastic leukemia. Since then, Dr. Brown’s scientific interests have transitioned more towards the design and testing of innovative approaches that incorporate molecularly targeted agents either to the tumor itself or its microenvironment for the treatment of pediatric cancers. Because of her extensive experience in translating pre-clinical, scientific observations into feasible regimens, Dr. Brown is able to make significant contributions to collaborative teams, such as Beat Childhood Cancer, in order to deliver innovative, effective treatments more efficiently to childhood cancer patients.
[/x_tab][x_tab active=”true”]

[/x_tab][x_tab active=”false”]Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, Grupp SA. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA. 100: 15113-15118 (2003)

Brown VI, Hulitt J, Fish J, Sheen C, Bruno M, Xu Q, Carroll M, Fang J, Teachey DT, Grupp SA. Thymic stromal-derived lymphopoietin (TSLP) induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for IL-7Ra signaling. Cancer Research. 67(20): 9963-9970 (October 2007)

Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunological Research. 42(1): 84-105 (October 2008)

DiNardo L, Brown V, Perez E, Bunin N, Sullivan K. A Single Center Study of Hematopoietic Stem cell Transplantation for Primary Immune Deficiencies (PIDD). Pediatric Transplantation. 16(1):63-72 (February 2012)

Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Guilcher GMT, Hayashi RJ, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah NN, Thiel E, Kitko CL. Transplant Outcomes for Children with T-Cell Acute Lymphoblastic Leukemia in Second Remission: A Report of the CIBMTR®. Biology of Blood and Marrow Transplantation. 21(12): 2154-2159 (December 2015)

Khandelwal P, Millard HR, Thiel E, Abdel-Azim H, Abraham AA, Auletta JJ, Boulad F, Brown VI, Camitta BM, Chan KW, Chaudhury S, Cowan MJ, Angel-Diaz M, Gadalla SM, Gale RP, Hale G, Kasow KA, Keating AK, Kitko CL, MacMillan ML, Olsson RF, Page KM, Seber A, Smith AR, Warwick AB, Wirk B, Mehta PA. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A CIBMTR Report. Biology of Blood and Marrow Transplantation. doi:10.1016/j.bbmt.2017.04.018 [Epub ahead of print].

Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, Brown VI, Chan KW, Diaz MA, Dietz A, Vincent MG, Guilcher G, Hale G, Hayashi RJ, Keating A, Mehta P, Myers K, Page K, Prestige T, Shah N, Smith AR, Woolfrey A, Thiel E, Davies SM, Eapen M. Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplant. Biology of Blood and Marrow Transplantation, doi: 10.1016/j.bbmt.2017.05.011 [Epub ahead of print]
[/x_tab][/x_tabs][/cs_column][/cs_row][/cs_section][/cs_content]